New York City, NY, United States
New York City, NY, United States

The Icahn School of Medicine at Mount Sinai , formerly the Mount Sinai School of Medicine , is an American medical school in the New York City borough of Manhattan in the state of New York. Chartered by Mount Sinai Hospital in 1963, the ISMMS is one of the foremost medical schools in the United States, ranking 19th in research according to U.S. News & World Report, 18th in NIH funding among U.S Medical Schools , and 3rd in NIH funding per primary investigator.ISMMS and the Mount Sinai Hospital occupy a four-block area adjacent to Central Park on the Upper East Side of Manhattan, with architecture designed by I. M. Pei. ISMMS and Mount Sinai Hospital comprise the Mount Sinai Medical Center, of which Kenneth L. Davis, MD, is the president and CEO.In 2012–13, The Mount Sinai Medical Center was recognized on the U.S. News & World Report "Best Hospitals Honor Roll," ranking 14th among the approximately 5000 hospitals in the US with 11 nationally ranked specialties including cancer, geriatrics, gastroenterology, cardiology & heart surgery, otolaryngology, rehabilitation, diabetes & endocrinology, neurology & neurosurgery, gynecology, urology, and kidney disorders. Wikipedia.


Time filter

Source Type

The present disclosure relates to methods for the treatment of sarcoidosis. In certain aspects and embodiments, the disclosure provides compositions containing 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof and/or the use of such compositions for the treatment of Sarcoidosis. In another aspect, the disclosure relates to compositions containing 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof plus a second active agent. In yet another aspect, the disclosure relates to kits containing agents useful for the treatment of sarcoidosis.


Patent
Mount Sinai School of Medicine | Date: 2016-11-21

The present invention provides methods for treating pulmonary hypertension in a subject by delivering a therapeutic adeno-associated virus (AAV)-SERCA2 composition to a subject in need thereof.


Patent
Mount Sinai School of Medicine | Date: 2016-11-03

Modified nucleic acid adapters are provided that collectively provide a mixture of nucleotides at the 3 end of 5 adapters and at the 5 end of 3 adapters such that at least one adapter in each set has any given nucleotide at position 1, i.e., the nucleotide position available for ligation to a small RNA, and has any given nucleotide at position 2 adjacent to position 1 for use in overcoming bias during nucleic acid manipulation, such as small RNA characterization and/or profiling by, e.g., deep sequencing, along with methods for use of the modified adapters in small RNA characterization. The modified adapters have at least two mixed nucleotides at the adapter terminus to be ligated to a nucleic acid such as a small RNA.


Patent
Mount Sinai School of Medicine | Date: 2016-03-03

The present invention provides chimeric negative-stand RNA viruses that allow a subject, e.g., an avian, to be immunized against two infectious agents by using a single chimeric virus of the invention. In particular, the present invention provides chimeric influenza viruses engineered to express and incorporate into their virions a fusion protein comprising an ectodomain of a protein of an infectious agent and the transmembrane and cytoplasmic domain of an influenza virus protein. Such chimeric viruses induce an immune response against influenza virus and the infectious agent. The present invention also provides chimeric Newcastle Disease viruses (NDV) engineered to express and incorporate into their virions a fusion protein comprising the ectodomain of a protein of an infectious agent and the transmembrane and cytoplasmic domain of an NDV protein. Such chimeric viruses induce an immune response against NDV and the infectious agent.


Patent
Abbott Laboratories and Mount Sinai School of Medicine | Date: 2016-06-22

The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies or antibody fragments. In certain embodiments, the lipid binding domain monoclonal antibody or antibody fragment recognizes an epitope in amino acids 141 to 161 of HCV core protein and the DNA binding domain antibody or antibody fragment recognizes an epitope in amino acids 95-123 (e.g., in amino acids 99-117) of HCV core protein.


Patent
Mount Sinai School of Medicine | Date: 2017-04-12

The present invention relates to novel Prothymosin Alpha (ProT) variants that are capable of inducing cell-mediated immune responses. These variants lack a nuclear localization signal and the proliferative oncogenic activity previously attributed to ProT. The variants of the invention are used in methods of treating, for example, viral infections, bacterial infections, fungal infections, cancer, ischemia and myeloproliferative blood disorders. Administration of a ProT variant to a subject in a therapeutically effective amount treats the infection or disease.


Patent
King's College London and Mount Sinai School of Medicine | Date: 2016-12-28

Disclosed herein is a recombinant adeno-associated virus (AAV) vector comprising (a) a variant AAV2 capsid protein, wherein the variant AAV2 capsid protein comprises at least four amino acid substitutions with respect to a wild type AAV2 capsid protein; wherein the at least four amino acid substitutions are present at the following positions in an AAV2 capsid protein sequence: 457, 492, 499 and 533; and (b) a heterologous nucleic acid comprising a nucleotide sequence encoding a gene product.


The present disclosure relates to methods for the treatment of sarcoidosis. In certain aspects and embodiments, the disclosure provides compositions containing 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof and/or the use of such compositions for the treatment of Sarcoidosis. In another aspect, the disclosure relates to compositions containing 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof plus a second active agent. In yet another aspect, the disclosure relates to kits containing agents useful for the treatment of sarcoidosis.


Blander J.M.,Mount Sinai School of Medicine
Nature Reviews Immunology | Year: 2014

Historically, cell death and inflammation have been closely linked, but the necessary divergence of the fields in the past few decades has enriched our molecular understanding of the signalling pathways that mediate various programmes of cell death and multiple types of inflammatory responses. The fields have now come together again demonstrating a surprising level of integration. Intimate interconnections at multiple levels are revealed between the cell death and inflammatory signal transduction pathways that are mobilized in response to the engagement of pattern recognition receptors during microbial infection. Molecules such as receptor-interacting protein kinase 1 (RIPK1), RIPK3, FAS-associated death domain protein (FADD), FLICE-like inhibitory protein (FLIP) and caspase 8-which are associated with different forms of cell death-are incorporated into compatible and exceedingly dynamic Toll-like receptor, NOD-like receptor and RIG-I-like receptor signalling modules. These signalling modules have a high capacity to switch from inflammation to cell death, or a programmed execution of both, all in an orchestrated battle for host defence and survival. © 2014 Macmillan Publishers Limited.


Lunnon K.,Mount Sinai School of Medicine
Nature neuroscience | Year: 2014

Alzheimer's disease (AD) is a chronic neurodegenerative disorder that is characterized by progressive neuropathology and cognitive decline. We performed a cross-tissue analysis of methylomic variation in AD using samples from four independent human post-mortem brain cohorts. We identified a differentially methylated region in the ankyrin 1 (ANK1) gene that was associated with neuropathology in the entorhinal cortex, a primary site of AD manifestation. This region was confirmed as being substantially hypermethylated in two other cortical regions (superior temporal gyrus and prefrontal cortex), but not in the cerebellum, a region largely protected from neurodegeneration in AD, or whole blood obtained pre-mortem from the same individuals. Neuropathology-associated ANK1 hypermethylation was subsequently confirmed in cortical samples from three independent brain cohorts. This study represents, to the best of our knowledge, the first epigenome-wide association study of AD employing a sequential replication design across multiple tissues and highlights the power of this approach for identifying methylomic variation associated with complex disease.

Loading Mount Sinai School of Medicine collaborators
Loading Mount Sinai School of Medicine collaborators